Medicure Comments on Recent Trading Activity
April 15 2014 - 2:02PM
Marketwired
Medicure Comments on Recent Trading Activity
WINNIPEG, MANITOBA--(Marketwired - Apr 15, 2014) - Medicure Inc.
("Medicure" or the "Company") (TSX-VENTURE:MPH)(OTCQB:MCUJF), a
specialty pharmaceutical company, reports that, in view of the
recent market activity in the Company's stock, the Investment
Industry Regulatory Organization of Canada ("IIROC") has contacted
the Company in accordance with its usual practice.
Although the Company ordinarily does not comment on market
activity or market speculation, the Company is aware of the
increased market activity in its common stock subsequent to our
most recent press releases, including the announcement of March 26,
2014 relating to the financial results from the third quarter
fiscal 2014 and the announcement of April 14, 2014 relating to the
Company's advisory services agreement with Knight Therapeutics
Inc.
Over the past several years the Company has been exploring
opportunities to grow its business through acquisition. The Company
is currently pursuing one specific opportunity, under which the
Company would be a party to an acquisition. There is no assurance
that this potential transaction, or any other transaction, is going
to be completed.
The transaction contemplated is subject to, among other things,
the negotiation and execution of a definitive binding agreements
and other documentation, approval of the board of directors of the
Company and that of the other parties to the transaction, and the
completion of remaining due diligence activities. There can be no
assurance that these conditions precedent, or any other conditions
precedent, will be satisfied.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the
development and commercialization of novel small molecule
therapeutics. The primary focus of the Company and its subsidiaries
is the marketing and distribution of AGGRASTAT (tirofiban HCl) for
non-ST elevation acute coronary syndrome in the United States,
where it is sold through the Company's U.S. subsidiary, Medicure
Pharma, Inc. For more information on Medicure please visit
www.medicure.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.com/newsreleases.html.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release. Forward Looking Information Statements contained in
this press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, including the potential
for any growth through acquisition, are based on the current
assumptions, estimates, analysis and opinions of management of the
Company made in light of its experience and its perception of
trends, current conditions and expected developments, as well as
other factors which the Company believes to be relevant and
reasonable in the circumstances. Inherent in forward-looking
statements are known and unknown risks, uncertainties and other
factors beyond the Company's ability to predict or control that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements, and as such, readers
are cautioned not to place undue reliance on forward-looking
statements. Such risk factors include, among others, the Company's
future product revenues, stage of development, additional capital
requirements, risks associated with the completion and timing of
clinical trials and obtaining regulatory approval to market the
Company's products, the ability to protect its intellectual
property, dependence upon collaborative partners, changes in
government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on
a number of assumptions which may prove to be incorrect, including,
but not limited to, assumptions about: general business and
economic conditions; the impact of changes in Canadian-US dollar
and other foreign exchange rates on the Company's revenues, costs
and results; the timing of the receipt of regulatory and
governmental approvals for the Company's research and development
projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or
the availability of financing on reasonable terms; results of
current and future clinical trials; the uncertainties associated
with the acceptance and demand for new products and market
competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended May 31, 2013.
Medicure Inc.Dawson ReimerPresident &
COO888-435-2220204-488-9823info@medicure.comwww.medicure.com
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Apr 2023 to Apr 2024